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We have recently shown that upregulation of glutamate transporter 1 (GLT1) in
the brain is associated in part with reduction in ethanol intake in alcohol-preferring
(P) male rats. In this study, we investigated the effects of a synthetic compound,
(R)-(−)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153), known to activate GLT1 on ethanol
consumption as well as GLT1 expression and certain signaling pathways in P rats. P rats
were given 24-h concurrent access to 15 and 30% ethanol, water and food for 5 weeks.
On week 6, P rats received MS-153 at a dose of 50mg/kg (i.p.) or a vehicle (i.p.) for 5
consecutive days. We also tested the effect of MS-153 on daily sucrose (10%) intake.
Our studies revealed a significant decrease in ethanol intake at the dose of 50mg/kg
MS-153 from Day 1 through 14. In addition, MS-153 at dose of 50mg/kg did not induce
any significant effect on sucrose intake. Importantly, we found that MS-153 upregulated
the GLT1 level in the nucleus accumbens (NAc) but not in the prefrontal cortex (PFC).
In accordance, we found upregulation of nuclear NFkB-65 level in NAc in MS-153-treated
group, however, IkBα was downregulated in MS-153-treated group in NAc. We did not
find any changes in NFkB-65 and IkBα levels in PFC. Interestingly, we revealed that p-Akt
was downregulated in ethanol vehicle treated groups in the NAc; this downregulation
was reversed by MS-153 treatment. We did not observe any significant differences in
glutamate aspartate transporter (GLAST) expression among all groups. These findings
reveal MS-153 as a GLT1 modulator that may have potential as a therapeutic drug for
the treatment of alcohol dependence.
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INTRODUCTION
Deficits in glutamate uptake have been suggested to impair
neurocircuits involved in drug abuse and drug-seeking behav-
ior, affecting many aspects of neuroplasticity associated with
ethanol and drug addiction. A key source of dependency is
thought to be alcohol-induced changes in glutamate transmission
(Smith, 1997; Smith and Weiss, 1999). Ethanol-seeking behavior
is promoted by increased glutamate transmission in key regions
of the mesocorticolimbic reward circuit (Selim and Bradberry,
1996; Quertemont et al., 1998; Dahchour et al., 2000; Roberto
et al., 2004; Melendez et al., 2005; Kapasova and Szumlinski,
2008). Moreover, in vitro and in vivo studies have demonstrated
that ethanol exposure affects glutamate transport (Smith, 1997;
Smith and Weiss, 1999; Othman et al., 2002; Melendez et al.,
2005). It is noteworthy that glutamate transporter 1 (GLT1) is
responsible for the removal of most of the extracellular glu-
tamate (Ginsberg et al., 1995; Rothstein, 1995; Danbolt, 2001;
Mitani and Tanaka, 2003). Studies have shown that ceftriax-
one, a β-lactam antibiotic, has an upregulatory effects in GLT1
levels (Rothstein et al., 2005; Miller et al., 2008; Sari et al.,
2009, 2010). Ceftriaxone was found to normalize the gluta-
mate transport capacity and basal glutamate levels after chronic
drug addiction (Trantham-Davidson et al., 2012). Studies from
our lab and others have demonstrated that ceftriaxone attenu-
ated cue-induced reinstatement of cocaine-seeking behavior (Sari
et al., 2009; Knackstedt et al., 2010). We have recently shown
that ceftriaxone treatment reduced ethanol intake in alcohol-
preferring (P) rats (Sari et al., 2011, 2013a) and attenuated
relapse-like to ethanol-drinking behavior (Qrunfleh et al., 2013).
The behavioral effects of ceftriaxone were associated with upreg-
ulation of GLT1 in the prefrontal cortex (PFC) and nucleus
accumbens (NAc).
We focused here on testing a new synthetic compound, a
non-β-lactam antibiotic, which regulates glutamate transmis-
sion for potential attenuation of ethanol intake in male P
rats. We also focused on the effects of this compound in
GLT1 expression. Thus, we studied MS-153 [(R)-(−)-5-methyl-
1-nicotinoyl-2-pyrazoline], a novel pyrazoline compound found
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to be a neuroprotective agent, which decreased the extracel-
lular glutamate level in the ischemic penumbra zone during
permanent occlusion of the middle cerebral artery (Kawazura
et al., 1997). The compound has been suggested to act as
a GLT1 activator, which increases the activity of GLT1 and
thus accelerates glutamate uptake (Shimada et al., 1999). MS-
153 has the ability to enhance glutamate uptake or decrease
glutamate release, which both attenuate the development of
behavioral sensitization to phencyclidine-induced stereotypies
(Abekawa et al., 2002). Studies have demonstrated that admin-
istration of MS-153 decreased the development of morphine
tolerance and physical dependence in mouse models (Nakagawa
et al., 2001). Furthermore, administration of MS-153 attenu-
ated the induction of conditioned place preference to morphine,
methamphetamine and cocaine without affecting acute loco-
motor responses (Nakagawa et al., 2001, 2005). In this study,
we tested whether MS-153 treatment would attenuate ethanol
intake in P rats. We also determined the effect of MS-153 on
sucrose intake as an appetitive control for drinking-motivated
behavior in male P rats. We further determined the effects of
MS-153 on GLT1 levels in both PFC and NAc. We then focused
our study on investigating certain signaling pathways involv-
ing MS-153 in the regulation of GLT1 levels in the NAc and
PFC. Based on recent studies showing the existence of a link
between GLT1 and NF-kB and Akt pathways (Lee et al., 2008;
Wu et al., 2010), we endeavored to investigate the effects of
MS-153 on these pathways. We also determined the effects of MS-




MS-153 [(R)-(−)-5-methyl-1-nicotinoyl-2-pyrazoline] (Figure 1)
was synthesized in-house at Columbia University using a chi-
ral silane Lewis acid-promoted acylhydrazone-enol ether [3 + 2]
cycloaddition that delivers the pyrazolidine product in 98% enan-
tiomeric excess (ee). Nicotinoylation of the pyrazolidine product
is followed by cleavage of the p-nitrobenzamide and concomitant
t-butoxide elimination to provideMS-153 in 70% overall yield for
the three-step sequence. Full experimental details regarding MS-
153 synthesis can be found in the previous study by our group
(Tran and Leighton, 2006).
FIGURE 1 | (R)-(−)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153)
structure.
ANALYTICAL PROCEDURE AND QUANTITATIVE DETERMINATION OF
M-153 IN MALE P RAT PLASMA AND CSF
A high-performance liquid chromatography system (HPLC)
(Waters Alliance 2695 separation module, Milford, MA)
equipped with a Kinetex C18 column (250 × 4.6mm,
Phenomenex) and UV/Visible detector was used for analy-
sis. MS-153 was analyzed by an isocratic method with a mobile
phase containing water and acetonitrile (85:15) pumped at a flow
rate of 1ml/min. The retention time of MS-153 (λmax = 260 nm)
was found to be 7min. Different calibration standards of MS-153
were prepared in the mobile phase. For the calibration curve, each
standard was analyzed in triplicate, and the average peak area was
plotted against concentration. The drug content was determined
quantitatively by plotting a calibration curve. The assay method
was found to be linear in the range of 0.015625–10μg/ml, with
a correlation coefficient of 0.9999. The percentage recovery of
MS-153 ranged from 99.97 to 101.66%. The limit of detection
and limit of quantification of MS-153 were found to be 2.98
and 9.92 ng/ml, respectively. The intra- and inter-day precisions
(measured by %RSD) were found to be in the ranges of 0.21–
0.55% and 0.32–0.82%, respectively. Plasma and CSF samples
were mixed with equal amounts of methanol and vortexed for
30 s. The mixture was then centrifuged at 5000 rpm for 10min.
The supernatant was further analyzed using HPLC.
ANIMALS AND ETHANOL DRINKING PARADIGM
Male adult P rats were received from Indiana University School
of Medicine, Indianapolis, at the age of 21–30 days. Rats were
housed in the Department of Laboratory Animal Resources,
University of Toledo, in standard plastic tubs with corn-cob bed-
ding and had ad lib access to chow food and water throughout the
experimental procedures. P rats were acclimated at a temperature
of 25◦C and 50% humidity in a 12-h light/dark cycle. We used
P rats as a model of ethanol dependence, which demonstrated
in previous studies (Stewart et al., 1991). Animal experimen-
tal procedures were approved by the Institutional Animal Care
and Use Committee of The University of Toledo in accordance
with the guidelines of the Institutional Animal Care and Use
Committee of the National Institutes of Health and the Guide for
the Care and Use of Laboratory Animals (Institute of Laboratory
Animal Resources, Commission on Life Sciences, 1996). The
programs and procedures are accredited by the Association for
the Assessment and Accreditation of Laboratory Animal Care,
International.
P rats started the experimental procedures at the age of 90
days old. Three experimental groups were tested for the effects
of MS-153 on ethanol intake, water intake and body weight. (1)
The naïve ethanol vehicle (Naïve) group was exposed to water
and food only and received i.p. injections of vehicle solution (1%
DMSO in PBS), n = 11; (2) Ethanol vehicle group (ethanol con-
trol group) received i.p. injections of vehicle, n = 15; and (3)
Ethanol MS-153 group received a dose of 50mg/kg, i.p., n =
13. Ethanol vehicle and ethanol MS-153 groups had free-choice
access to water, 15 and 30% ethanol and food throughout the
experimental procedures.
At the age of 90 days, male P rats were exposed to continuous
access of free choice of ethanol (15 and 30%, v/v, concurrently),
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water and ad libitum food for 5 weeks. The naïve ethanol vehicle
group had access to ad libitum food and water. For the ethanol
vehicle and ethanol MS-153 groups, ethanol consumption was
measured as grams of ethanol consumed per kilogram of rat body
weight per day for 5 weeks. The average measurements taken
across the last 2 weeks of the 5 weeks of consumed ethanol and
water were calculated as the baseline. The average measurements
of ethanol intake were based on cumulative consumption of 15
and 30% ethanol. The measurements of consumed ethanol were
evaluated to the nearest 1/10 of a gram by subtracting the bottle
weight from its initial weight containing ethanol. These measure-
ments were converted using a densitometry formula to the actual
grams of consumed ethanol per kg of rat body weight per day.
On week six, rats were injected with 50mg/kg of MS-153 or with
vehicle at around 11:00 a.m. once a day for 5 days. Ethanol intake,
water intake and rat body weight were measured daily for 14 days,
starting on the first day of the vehicle and MS-153 i.p. injections.
SUCROSE DRINKING PARADIGM
We further tested the effects ofMS-153 on sucrose (10%) intake as
an appetitive control, drinking-motivated behavior. Animals were
exposed to continuous access to 10% sucrose solution, water, and
food for 3 weeks. On Week 4, a group of P rats (n = 7) received
the vehicle and another group (n = 5) received 50mg/kg of MS-
153 (i.p.) for 5 consecutive days. Sucrose was available 6 days after
the first day of MS-153 and vehicle i.p. injections. Body weight
and sucrose and water intake were measured daily for 6 days
starting on the first day of the vehicle or MS-153 i.p. injections.
BRAIN TISSUE HARVESTING
On the last day of the drinking paradigm of each study, all the ani-
mals were euthanized by CO2 inhalation and rapidly decapitated
with a guillotine; their brains were dissected and immediately
frozen on dry ice and stored at −70◦C. The PFC and NAc
were microdissected stereotaxically using a cryostat apparatus,
as described recently (Sari and Sreemantula, 2012). We followed
the stereotaxic coordinates for the rat brain for identification of
the PFC and NAc (Paxinos and Watson, 2007). We used surgical
blades to isolate the PFC and NAc through visualized landmarks.
The PFC (medial part) was isolated at the same level of NAc.
The PFC and NAc were extracted for Western blot procedures for
detection of GLT1, GLAST, NF-kB-p65, IkBα, phospho-Akt, Akt,
Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH), lamin,
and β-tubulin.
WESTERN BLOT PROTOCOL FOR DETECTION OF GLT1, GLAST,
PHOSPHO-Akt AND TOTAL-Akt
GLT1, GLAST, β-tubulin, total-Akt, phospho-Akt, and
Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) lev-
els were determined in NAc and PFC of the naïve ethanol,
ethanol vehicle, and ethanol MS-153 groups using Western
blot assay. The NAc and PFC were homogenized in lysis buffer
containing protease inhibitor and phosphatase inhibitor. Proteins
from each brain region were extracted for immunoblotting.
Equal amounts of extracted protein were mixed with 5x Laemmli
loading dye and further separated in 10–20% glycine gel (Life
Technologies). The proteins were then transferred onto nitro-
cellulose membranes using a transfer apparatus. Membranes
were incubated overnight in blocking buffer at 4◦C with one
of the following antibodies: guinea pig-anti GLT1 antibody
(1:5000; Millipore), rabbit anti-GLAST (dilution: 1:5000),
rabbit anti-phospho-Akt (1:5000, Cell Signaling Technology),
mouse anti-Akt (1:5000, Cell Signaling Technology), mouse anti
β-tubulin antibody (1:5000; Covance), or mouse anti-GAPDH
antibody (1:5000; Millipore). Membranes were then washed
and incubated with horseradish peroxidase (HRP) donkey-anti-
Guinea pig IgG (H+ L) secondary antibody (1:5000), anti-mouse
IgG, HRP-linked secondary antibody (1:5000), or anti-rabbit
IgG, HRP-linked secondary antibody (1:5000). Membranes
were incubated with a chemiluminescent kit (SuperSignal West
Pico) for protein detection. Membranes were then exposed
to Kodak BioMax MR films (Thermo Fisher Scientific), and
films were developed using an SRX-101A machine. Blots for
each detected protein were digitized and quantified using an
FIGURE 2 | Diagram showing the sample chromatograms of MS-153 in plasma (A) and CSF (B) (n = 4). The X-axis represents the retention time of
MS-153 in minutes and the Y-axis represents the absorbance of MS-153 in absorbance units.
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FIGURE 3 | (A) Effects of MS-153 treatment on ethanol intake in male P
rats exposed to 5 weeks of free choice of ethanol and water. Vehicle
(n = 7), and MS-153 50mg/kg (n = 5). Statistical analyses exhibited a
significant decrease in ethanol consumption with MS-153 (50mg/kg, i.p.)
from Day 1 (24 h after the first i.p. injection) through Day 5 compared to the
ethanol vehicle group. (B) Effects of MS-153 treatment on water intake in P
rats exposed to 5 weeks of free choice of ethanol and water. Statistical
analyses exhibited a significant increase in water consumption with MS-153
(50mg/kg, i.p.) on Days 1, 3, and 4 compared to the ethanol vehicle group.
(C) Effects of MS-153 treatment on body weight. Statistical analyses did
not demonstrate any significant effect on body weight. Values shown as
means ± s.e.m. (∗p < 0.05; ∗∗p < 0.01).
MCID system. Data were calculated as ratios of GLT1/β-tubulin,
GLAST/GAPDH, and phospho-Akt/total-Akt.
WESTERN BLOT FOR DETECTION OF NF-kb-p65 AND IkBα IN NUCLEAR
OR CYTOPLASMIC FRACTION
Brain samples (NAc and PFC) were homogenized in buffer A
[10mM HEPES-KOH, pH 7.9; 1.5mM MgCl2; 10mM KCl;
1mM Dithiothreitol (DDT); 1mM phenylmethylsulfonyl fluo-
ride (PMSF); 10 uL of protease inhibitor cocktail/ml of buffer]
FIGURE 4 | (A) Effects of MS-153 treatment and post-treatment on daily
ethanol intake in male P rats exposed to 5 weeks of free choice of ethanol
and water. Vehicle (n = 8), and MS-153 50mg/kg (n = 8). Statistical
analyses demonstrated a significant decrease in ethanol intake with the
MS-153 (50mg/kg, i.p.) treated group from Day 1 (24 h after the first i.p.
injection) through Day 14 (10 days after the last injection) as compared to
ethanol vehicle group. (B) Effects of MS-153 treatment on water intake in P
rats exposed to 5 weeks of free choice of ethanol and water. Statistical
analyses demonstrated a significant increase in water consumption on days
3–8. (C) Effects of MS-153 treatment on body weight. Statistical analyses
did not demonstrate any significant effects of MS-153 on body weight.
Values shown as means ± s.e.m. (∗p < 0.05; ∗∗p < 0.01).
and then incubated at 4◦C for 10min before addition of Nonidet
P40 to a final concentration of 0.1%. Brain samples were then
incubated for 2min at 4◦C and centrifuged at 13,200 rpm
for 15min at 4◦C. The supernatant was removed, and NaF,
Na-vanadate and Na-pyrophosphate were added to the final
concentrations of 50, 10, and 0.1mM, respectively, to obtain
the cytosolic fraction. The pellet was re-suspended in another
buffer [20mM HEPES-KOH, pH 7.9; 25% glycerol; 420mM
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FIGURE 5 | Effects of MS-153 on sucrose intake in P rats. Vehicle (n = 7)
and MS-153 50mg/kg (n = 5). MS-153 at the higher dose (50mg/kg, i.p.) did
not induce any effect on sucrose intake. Values shown as means ± s.e.m.
NACl; 1.5mM MgCl2; 1mM DDT; 1mM PMSF; 0.2mM EDTA;
50mM NaF; 10mM Na vanadate; 0.1mM Na pyrophosphate;
10 uL of protease inhibitor cocktail/ml of buffer] and incu-
bated in ice for 30min. The samples were then centrifuged at
13,200 rpm at 4◦C, and supernatant was collected as the nuclear
fraction.
Using Western blot as described earlier, we detected NF-kB,
IkBα, Lamin, and GAPDH. We used the following antibodies to
detect these proteins: anti-GAPDH antibody (1:5000; Millipore),
Anti IkB-α (1:500; Santa Cruz biotechnology, Inc.), anti Lamin
A/C (1:5000; Santa Cruz biotechnology, Inc.), and NF-kB p65
antibody (1:500; Cell signaling technology).
STATISTICAL ANALYSIS
General Linear Model (GLM) repeated measures were used in
this study for statistical analysis (SPSS) of ethanol consump-
tion, water and sucrose intake, and body weight measurements
for 24 h after the last i.p. injections of MS-153 (50mg/kg, i.p.)
for the short-term study, and 10 days after the last i.p. injection
to study the long-term effect of MS-153. Additionally, One-Way
ANOVA (SPSS) was performed to examine the day-wise effect
of treatment. Immunoblot data were statistically analyzed using
One-Way ANOVA, followed by Newman-Keuls’s test, for compar-
ison among the naïve ethanol vehicle, ethanol vehicle, and ethanol
MS-153 group. All statistical analyses were based on p < 0.05
level of significance.
RESULTS
DETECTION OF MS-153 IN PLASMA AND CSF
The plasma and CSF samples (n = 4) were cleaned to separate
MS-153 and then analyzed using HPLC. The mean concentra-
tions of MS-153 in plasma and CSF were found to be 14.74 ±
2.95μg/ml and 13.52 ± 4.0μg/ml, respectively. Sample chro-
matograms indicated the detection of MS-153 in plasma and CSF
(Figures 2A,B). As observed in the chromatograms, the reten-
tion time of MS-153 is approximately 7min in both plasma and
CSF samples. This indicates that the HPLC method of MS-153
is very specific and no interference was observed in the extracted
samples of plasma and CSF. The penetration of MS-153 into the
CSF after 1 h was substantial and comparable to concomitant
plasma levels. It is noteworthy that a complete in vivo pharma-
cokinetic study should be carried out in the future to determine
the CSF-to-serum ratio of the areas under the curves.
EFFECT OF MS-153 ON SHORT-TERM ETHANOL DRINKING BEHAVIOR,
WATER INTAKE, AND BODY WEIGHT
GLM repeated measures revealed a significant main effect of
Day on ethanol intake [F(1, 5) = 10.432, p < 0.0001] and a
significant Treatment × Day interaction [F(1, 5) = 7.476, p <
0.0001]. One-Way ANOVA demonstrated a significant reduc-
tion in ethanol intake among all animals treated with MS-153
at the dose of 50mg/kg (p < 0.01) compared to ethanol vehi-
cle animals (Figure 3A). In addition, GLM repeated measures
revealed a significant main effect of Day on water intake [F(1, 5) =
3.802, p < 0.01] but did not show a significant Treatment ×
Day interaction [F(1, 5) = 2.379, p > 0.05]. However, One-Way
ANOVA demonstrated a significant increase in water intake in
the MS-153 50 group on Days 1 and 3 (p < 0.05) and on Day
4 (p < 0.01) (Figure 3B). Furthermore, GLM repeated measures
revealed a significant main effect of Day on body weight [F(1,5) =
20.024, p < 0.0001] and a significant Treatment × Day inter-
action [F(1,5) = 49.887, p < 0.0001]. One-Way ANOVA did not
reveal a significant effect on body weight among the ethanol
vehicle and ethanol MS-153 50 groups (Figure 3C).
EFFECT OF MS-153 ON LONG-TERM ETHANOL DRINKING BEHAVIOR,
WATER INTAKE, AND BODY WEIGHT
We next examined the long-lasting effect of MS-153 on ethanol
drinking behavior at the dose 50mg/kg. GLM repeated measures
revealed a significant main effect of Day [F(1, 14) = 19.839; p <
0.0001] and a significant Treatment × Day interaction [F(1, 14) =
2.814; p < 0.01]. One-Way ANOVA revealed a significant reduc-
tion in ethanol intake in the MS-153 50 group compared to the
ethanol vehicle group from Days 1 to 14 (p < 0.01) (Figure 4A).
Furthermore, GLM repeated measures demonstrated a significant
main effect of Day on water intake [F(1, 14) = 3.512, p < 0.0001]
and a significant Treatment × Day interaction [F(1, 14) = 2.39,
p < 0.01]. One-Way ANOVA demonstrated a significant increase
in water intake in the MS-153 50 group compared to the ethanol
vehicle group on Days 3–8 (p < 0.05, p < 0.05) (Figure 4B).
In addition, GLM repeated measures demonstrated a significant
main effect of Day on body weight [F(1, 14) = 5.147, p < 0.0001]
and a significant Treatment × Day interaction [F(1, 14) = 19.618,
p < 0.0001]. However, One-Way ANOVA did not reveal a signif-
icant difference in body weight between the ethanol vehicle and
ethanol MS-153 50 groups (Figure 4C).
EFFECT OF MS-153 ON SUCROSE DRINKING BEHAVIOR
We tested the effects of MS-153 at 50mg/kg on sucrose consump-
tion (Figure 5). GLM repeated measures revealed a significant
main effect of Day [F(1, 5) = 7.475, p < 0.0001], which indicated
that sucrose intake decreased in both groups across days, while,
the Treatment × Day interaction was not significant [F(1, 5) =
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FIGURE 6 | Effects of MS-153 (50mg/kg) on GLT1 expression level in
NAc. (A,C) Immunoblots for GLT1 and β-tubulin, which was used as a
control loading protein, in the NAc after 1 day and 10 days of the last i.p.
injection of MS-153, respectively. (B,D) Quantitative analysis revealed a
significant increase in the ratio of GLT1/β-tubulin in MS-153-treated groups
compared to the ethanol vehicle groups after 1 day and 10 days of the last
i.p. injection of MS-153, respectively. Significant downregulation of GLT1
expression was revealed in the ethanol vehicle group compared to the
naïve ethanol group. Values shown as means ± s.e.m. (∗p < 0.05) (n = 5
for each group).
2.109, p > 0.05]. However, One-Way ANOVA did not reveal a
significant difference in sucrose intake throughout the treatment
period (p > 0.05). These data demonstrate that MS-153 did not
affect sucrose intake.
EFFECT OF MS-153 ON GLT1 EXPRESSION IN THE NAc AND PFC
We further investigated the effects of MS-153 on GLT1 expression
in the NAc 24 h after the last i.p. injections of MS-153 50mg/kg
(Figures 6A,B) and 10 days post-treatment (Figures 6C,D). One-
Way ANOVA analyses revealed a significant main effect among
the naïve ethanol vehicle, ethanol vehicle and ethanol MS-
153 treated groups in the NAc [F(2, 12) = 6.45, p = 0.012 for
short term; and F(2, 12) = 5.41, p = 0.02 for post-treatment].
The Newman-Keuls post-hoc test, a multiple comparison test,
demonstrated a significant increase in GLT1 expression in
the ethanol MS-153-treated group compared to the ethanol
vehicle-treated group 24 h after the last injection of MS-153
(p < 0.05; Figures 6A,B) and 10 days post-treatment (p < 0.05;
Figures 6C,D). Alternatively, statistical analyses revealed signifi-
cant downregulation of GLT1 expression in the ethanol vehicle
group compared to the naïve ethanol group in the NAc for both
paradigms (p < 0.05; Figures 6B,D).
Interestingly, One-Way ANOVA analyses did not reveal
any significant main effect among all groups in the PFC
(Figures 7A,B). Furthermore, in accordance with a recent study
from our lab (Sari and Sreemantula, 2012), we did not observe
downregulation of GLT1 expression in the PFC.
EFFECT OF MS-153 ON NF-kb-p65 AND IkBα LEVELS IN THE NAc
AND PFC
We next investigated the mechanism of action of MS-153 in
GLT1 upregulation. We focused on the effects of this drug on
NF-kB-p65 and IkBα levels in the NAc. In addition, we deter-
mined the levels of NF-kB-p65 and IkBα as well. One-Way
ANOVA analyses demonstrated a significant main effect on NF-
kB-p65 levels among all groups in the nuclear fraction of the NAc
[F(2, 12) = 5.309, p = 0.0223]. The Newman-Keuls post-hoc test,
a multiple comparison test, demonstrated a significant increase
in the NF-kB-p65 level of the MS-153 treated group (p < 0.05)
compared to the naïve ethanol vehicle and ethanol vehicle groups
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FIGURE 7 | Effects of MS-153 (50mg/kg) on GLT1 expression in PFC. (A)
Immunoblots for GLT1 and β-tubulin, which was used as a control loading
protein, in the PFC after 1 day of the last i.p. injection of MS-153. (B)
Quantitative analysis did not reveal any significant differences in the ratio of
GLT1/β-tubulin among all groups. Values shown as means ± s.e.m. (n = 5 for
each group).
(Figures 8A,B). Statistical analyses did not show any main effect
among all groups in the NF-kB-p65 level in the cytoplasmic frac-
tion [F(2, 12) = 0.458, p = 0.642] (Figures 8C,D). Furthermore,
statistical analyses revealed a significant main effect on IkBα levels
among tested groups [F(2, 12) = 5.404, p = 0.021]. The post-hoc
test revealed a significant decrease in the IkBα level (p < 0.05) of
the MS-153 treated group compared to the naïve ethanol vehicle
and ethanol vehicle groups in the cytoplasmic fraction of the NAc
(Figures 8E,F).
We further determined the levels of NF-kB-p65 and IkBα in
the PFC. One-Way ANOVA analyses did not show any signifi-
cant main effect among all groups in NF-kB-p65 level neither in
the nuclear fraction (Figures 9A,B) nor in cytoplasmic fraction
[F(3, 19) = 0.21, p = 0.887] (Figures 9C,D). In addition, we did
not find any significant main effect among all groups on the IkBα
level in the cytoplasmic fraction (Figures 9E,F).
EFFECT OF MS-153 ON Akt LEVEL IN THE NAc
We further explored other mechanisms of action ofMS-153 in the
NAc.We focused on Akt, which is known to regulate GLT1 expres-
sion in vitro (Li et al., 2006). One-Way ANOVA analyses demon-
strated a significant main effect on the phospho-Akt level among
all groups in the NAc 24 h after the last injection [F(2, 12) = 19.07,
p = 0.0002]. The Newman-Keuls post-hoc multiple comparisons
test revealed a significant decrease in the Akt level (p < 0.001) of
the ethanol vehicle group compared to the naïve ethanol vehicle
group in the NAc (Figures 10A,B). Importantly, we further found
that treatment with MS-153 upregulated phospho-Akt levels in
the NAc compared to the ethanol vehicle group (Figures 10A,B).
EFFECT OF MS-153 ON GLAST LEVEL IN THE PFC AND NAc
We further tested whether MS-153 affects another astroglial
transporter such as GLAST, which is co-expressed with GLT1.
Thus, we examined the effects of MS-153 on GLAST level
in both PFC and NAc. One-Way ANOVA analyses did not
reveal any significant differences between all tested groups in
PFC (Figures 11A,B) [F(2, 14) = 0.27, p = 0.76], and in NAc
(Figures 11C,D) [F(2, 14) = 0.64, p = 0.54].
DISCUSSION
We report here for the first time that administration of MS-153
(50mg/kg, i.p.) in P male rats reduced ethanol intake. We found
that MS-153 reduced ethanol intake dramatically. Importantly,
the effect of MS-153 on the reduction of ethanol intake was long-
lasting over a period of 10 days post-treatment. MS-153 had no
effect on sucrose intake, which indicates that the action of this
drug is specific to ethanol intake and does not affect sucrose as
an appetitive control, drinking-motivated behavior. It is note-
worthy that the reduction of ethanol intake was found alongside
upregulation of GLT1 in the NAc at 24 h after the last MS-153
i.p. injection and post-treatment. However, we did not find any
upregulatory effects with MS-153 in PFC. We also tested GLAST,
which is mainly found on the membranes of astroglial cells,
where it co-expresses with GLT1 throughout the brain (Berger
and Hediger, 1998). However, we did not find any significant
changes in the level of GLAST in PFC and NAc neither in MS-
153 treated rats nor in ethanol exposed rats, at least with the dose
used in this study. This suggests the specific regulatory effect of
MS-153 on GLT1 expression. Note that we did not observe any
downregulation of GLAST level in both PFC and NAc in ethanol
exposed rats. Accordingly, we recently reported that ceftriaxone
treatment upregulated the levels of GLT1 isoforms in both PFC
and NAc but no effect in GLAST level (Alhaddad et al., 2014).
We also found that MS-153 administered to P rats revealed
an increase in water intake compared to vehicle-administered
rats. These findings are in accordance with recent findings from
our lab in the investigation of other GLT1 upregulators (Sari
et al., 2011, 2013a,b; Sari and Sreemantula, 2012). We suggest
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FIGURE 8 | Effects of MS-153 at 50mg/kg (MS-153/50, n = 5),
vehicle (ethanol vehicle group, n = 5), naïve (naïve ethanol vehicle
group, n = 5) groups on NFκB-p65 level in the NAc. (A,C,E)
Immunoblots for GAPDH and Lamin [which were used as control
loading proteins for cytoplasmic extract (CE) and nuclear extract (NE)
proteins, respectively], NFκB-p65, and IκBα in CE and NE. (B,D)
Quantitative analysis of NFκB-p65 levels in the CE and NE revealed a
significant increase in the ratio of NFκB-p65/Lamin level in the NE but
not in the CE for the ethanol MS-153-treated group compared to the
naïve ethanol vehicle and ethanol vehicle groups. (F) Quantitative
analysis of IκBα level in the CE revealed a significant decrease in the
ratio of IκBα/GAPDH level in the ethanol MS-153-treated group
compared to the naïve ethanol vehicle and ethanol vehicle groups.
Values shown as means ± s.e.m. (∗p < 0.05).
that the increase in water intake is a behavioral mechanism to
compensate for the decrease in ethanol intake in MS-153 treated
groups.
It is noteworthy that a deficit or dysfunction of GLT1
plays a critical role in drug abuse, including alcohol and
cocaine (for review see Rao and Sari, 2012). We recently
reported that rats exposed to free-choice ethanol for 5 weeks
showed down-regulation of GLT1 levels in the NAc but not
in the PFC (Sari and Sreemantula, 2012; Sari et al., 2013b).
Furthermore, i.p. injections of ceftriaxone reduced ethanol con-
sumption in both male and female P rats (Sari et al., 2011,
2013a,b). We have further shown that ceftriaxone can also
attenuate relapse-like to ethanol-drinking behavior (Qrunfleh
et al., 2013). In addition, we have recently identified GPI-1046
(3-(3-pyridyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-
2-pyrrolidinecarboxylate) as another compound that reduced
ethanol intake in male P rats (Sari and Sreemantula, 2012). The
behavioral effects of ceftriaxone and GPI-1046 were associated
with upregulation of GLT1 in the NAc. In this study, we aimed
to determine the effect of a synthetic GLT1 activator, MS-153, on
GLT1 level and consequently its effect in ethanol intake. The drug
was shown to enhance glutamate uptake via GLT1 and prevent
Frontiers in Behavioral Neuroscience www.frontiersin.org October 2014 | Volume 8 | Article 366 | 8
Alhaddad et al. Effects of MS-153 in ethanol intake
FIGURE 9 | Effects of MS-153 at 50mg/kg (MS-153/50, n = 5), vehicle
(ethanol vehicle group, n = 5), naïve (naïve ethanol vehicle group,
n = 5) groups on NF-κB-p65 level in the PFC. (A,C,E) Immunoblots for
GAPDH and Lamin (which were used as control loading proteins for
cytoplasmic extract (CE) and nuclear extract (NE) proteins, respectively),
NF-κB-p65, and IκBα in CE and NE extracts. (B,D) Quantitative analysis of
NF-κB-p65 levels in CE and NE did not reveal any significant change in all
tested groups in the CE or NE. (F) Quantitative analysis of IκBα level in CE
did not reveal any significant change in IκBα level in tested groups. Values
shown as means ± s.e.m.
efflux of glutamate during cerebral ischemia (Shimada et al.,
1999).
Furthermore, studies demonstrated that MS-153 inhibits the
glutamatergic system, mainly by accelerating glutamate uptake;
the drug had no effect on NMDA glutamate receptors, AMPA
glutamate receptors, and Ca2+ channels (Nakagawa et al., 2005).
However, it was not known whether MS-153 could upregulate
GLT1 in the brain. In the present study, we further investigated
whether the effect of MS-153 on the reduction of ethanol intake
was associated in part with upregulation of the GLT1 level in the
NAc and PFC. Surprisingly, our findings showed that MS-153
upregulated GLT1 levels in NAc but not in PFC. Note that down-
regulation of GLT1 level was found in NAc but not in PFC. It
is clear that the drug prevented an ethanol-induced downregu-
lation of GLT1 level in the NAc. Since there were no effects in
ethanol exposure in PFC, we did not see any upregulatory action
of the drug in this region. Thus, the drug has normalized the
level of GLT1 affected by ethanol intake. This pharmacological
action of MS-153 suggests that the drug might be considered as
a modulator of the GLT1 level. Although, we demonstrated that
the upregulatory effect in GLT1 has lasted 10 days after the last
injection with the drug, it is noteworthy that the upregulatory
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FIGURE 10 | Effects of MS-153 at 50mg/kg (MS-153, n = 5), vehicle
(ethanol vehicle group, n = 5), naïve (naïve ethanol vehicle group, n = 5)
groups on phospho-Akt levels in the NAc. (A) Each panel presents
immunoblots for Total Akt and GAPDH, which was used as a control loading
protein, and phospho-Akt (PAkt) in the NAc. (B) Quantitative analysis revealed
a significant increase in the ratio of PAkt/total Akt in both MS-153-treated
groups compared to the ethanol vehicle group. Significant downregulation of
PAkt/total Akt expression was revealed in the ethanol vehicle group
compared to the naïve ethanol vehicle group. Values shown as means ±
s.e.m. (∗p < 0.01).
FIGURE 11 | Effects of MS-153 (50mg/kg) on GLAST expression in PFC
and NAc. (A,C) Immunoblots for GLAST and GAPDH, which was used as a
control loading protein, in the PFC and NAc, respectively. (B,D) Quantitative
analysis did not reveal any significant differences in the ratio of
GLAST/GAPDH among all groups in PFC and NAc, respectively. Values shown
as means ± s.e.m. (n = 5 for each group).
effect in GLT1 level with MS-153 may not be a permanent
effect.
Alternatively, similar to a recent study from our lab (Sari and
Sreemantula, 2012), we also found down-regulation of GLT1 level
in the NAc but not in the PFC. It is noteworthy that downregula-
tion of GLT1 level was also found in NAc but not PFC in cocaine
self-administered rats (Knackstedt et al., 2010). It is unclear in
how both ethanol and cocaine have similar effect in reduction of
GLT1 level. Although the neurochemistry leading to downregula-
tion of GLT1 level is different between ethanol and cocaine, we
suggest that the difference in the GLT1 levels might be due to
the fact that PFC has reciprocal glutamatergic connections with
other brain regions. However, NAc receives but does not send
glutamatergic projections to other brain regions. It is suggested
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FIGURE 12 | Diagram shows the signaling pathways involving the
effects of MS-153 in upregulation of GLT1. Under an unknown
mechanism, MS-153 administration may increase GLT1 transcription
through phosphorylation by IkB kinase of the IkB-p50–p65 complex, which
dissociated to p50–p65 and IkB. The nuclear translocation of p50–p65 can
lead to increased transcription of GLT1.
that neuroadaptations may occur due to the fact of the differ-
ences in anatomical distribution of this transporter in NAc and
PFC (Danbolt, 2001; Sari and Sreemantula, 2012).
Furthermore, it has been demonstrated in vitro that the upreg-
ulatory effect of ceftriaxone, a GLT1 upregulator, is mediated
through the transcription factor NF-kB pathway, which might
have direct or indirect interaction (Lee et al., 2008) (Figure 12).
Additionally, it has been shown that Akt activation is found to be
involved in GLT1 expression (Wu et al., 2010). Thus, we inves-
tigated whether the upregulatory effect in the NAc is mediated
through these pathways. Although we did not see any upregula-
tory effect of GLT1 in the PFC, we investigated these pathways
as well. The transcription factor, such as NF-kB, plays a criti-
cal role in various genes involved in cell growth, differentiation,
and immune responses (Karin, 2006; Massa et al., 2006). The NF-
kB family exists in five forms, including Rel (c-Rel), RelA (p65),
RelB, NF-nB1 (p50 and its precursor p105), and NF-nB2 (p52
and its precursor p100). The transcriptional activator form is a
heterodimer composed of p50 and p65, which is the most abun-
dant activated form (Emdad et al., 2006). NF-kB is an important
regulator for GLT1 expression (Sitcheran et al., 2005), which is
involved in positive and negative regulation of GLT1 expression,
depending on the agent administered (Su et al., 2003). Previous
in vitro studies have shown that ceftriaxone treatment increased
the GLT1 level by activating a GLT1 promoter through activation
of NF-kB signaling, inducing p65 translocation by means of pro-
teasomal degradation of IkBα (Lee et al., 2008). In this study, we
demonstrated that upregulation of the GLT1 level in the NAc is
associated with a significant increase in the NF-kB level of nuclear
extract inMS-153-treated group. This suggests the possible action
of MS-153 via the NF-kB pathway. NF-kB upregulation in the
nuclear fraction was also associated with downregulation of IkBα
in the cytoplasmic fraction, which indicates nuclear transloca-
tion of p65 and proteasomal degradation of IkBα. There were no
changes in the NF-kB neither in nuclear fraction nor in the IkBα
cytoplasmic fraction in the PFC, which correlates with no change
in the GLT1 level in this region. Our results did not show change
in the NF-kB level between naïve ethanol vehicle and ethanol
vehicle groups in the NAc and PFC. The multi-regulatory action
of NF-kB in many physiological and pathological processes may
underlie these results in P rats.
We further investigated the Akt signaling pathway in the
NAc since it has been shown in vitro that Akt is involved in
GLT1 upregulation as well (Li et al., 2006; Wu et al., 2010). We
found downregulation of phospho-Akt in the NAc of the ethanol
exposed group compared to the naïve ethanol vehicle group. This
finding is in accordance with studies that revealed downregula-
tion of Akt after chronic treatment with cocaine (Perrine et al.,
2008). Furthermore, we found that MS-153 treatment prevented
the deficit in the phospho-Akt level in the NAc. It is noteworthy
that the increases in the phospho-Akt level observed withMS-153
treatment correspond to the increases in GLT1 level in the NAc
compared to the ethanol-exposed group.
We conclude here thatMS-153 has the ability to reduce ethanol
consumption in P rats, which is associated, in part, with upregu-
lation and activation of GLT1 levels in NAc. These observations
suggest that the drug may have a modulatory effect in GLT1
expression. Furthermore, we found that MS-153 increased NF-
kB and phospho-Akt levels, which were well correlated with the
increased GLT1 level in the NAc. Note that there might be other
signaling pathways involved in MS-153-induced upregulation of
GLT1 level, which are warranted investigation. It is important to
note that we did not observe any effect of the drug in GLAST
expression in both PFC and NAc, which indicated the specific
action of MS-153 on GLT1 expression. These findings provide
ample information about the potential clinical application of
MS-153 as a novel drug for the treatment of alcohol dependence.
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